Aspart

DRUG6 trials

Sponsors

University of Texas Southwestern Medical Center, CPEX Pharmaceuticals Inc., Rush University Medical Center, Emory University, Mountain Diabetes and Endocrine Center

Conditions

DiabetesType 1 DiabetesType 1 Diabetes MellitusType 2 DiabetesType1 Diabetes Mellitus

Phase 2

Intranasal Insulin and Its Effect on Postprandial Metabolism in Comparison to Subcutaneous Insulin

WithdrawnNCT00850161

CPEX Pharmaceuticals Inc.Type 1 Diabetes Mellitus

Start: 2009-07-31End: 2010-09-30Updated: 2016-02-15

Phase 4

Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes

WithdrawnNCT00505882

University of Texas Southwestern Medical CenterType 1 Diabetes

Start: 2007-07-31End: 2008-12-31Updated: 2019-01-08

Carbohydrate Consumption as a Factor in Aspart Dosing

TerminatedNCT01333514

Rush University Medical CenterDiabetes

Start: 2011-04-30End: 2012-12-31Updated: 2023-05-01

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

CompletedNCT03336528

Emory UniversityType 2 Diabetes

Start: 2018-01-02End: 2021-03-01Updated: 2022-03-31

Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump

CompletedNCT04409587

Mountain Diabetes and Endocrine CenterType1 Diabetes Mellitus

Start: 2018-04-12End: 2020-11-01Updated: 2021-02-24

Unknown Phase

A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes

CompletedNCT05199714

McGill University Health Centre/Research Institute of the McGill University Health CentreType 1 Diabetes

Start: 2022-02-21End: 2023-03-25Updated: 2023-10-25

Related Papers

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01